Dr. Osama Gaber
Total: 18 projects
-
Source: NIAID
Type: Clinical Study Grant
Title: B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop de novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection
PI: Mohammed Sayegh, M.D.
Dates: Oct 2007-Jan 2010 -
Source: NIAID
Type: Clinical Study Grant (R34 Planning Grant)
Title: Effect of Dietary Supplements in African American Kidney Transplant Recipients
PI: A. Osama Gaber, M.D.
Dates: Sep 2007-Jan 2009 -
Source: Novartis
Type: Clinical Study Grant
Title: A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients
PI: A. Osama Gaber, M.D.
Dates: May 2008-May 2009 -
Source: Novartis
Type: Clinical Study Grant
Title: A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic® vs. a standard dosing regiment of Myfortic® in combination with Neoral® and Corticosteroids in de novo renal transplant patients
PI: A. Osama Gaber, M.D.
Dates: Dec 2007-Mar 2009 -
Source: LifeCycle Pharma
Type: Clinical Study Grant
Title: A phase II, open-label, multi-center prospective, conversion study in stable liver transplant patients to compare the pharmacokinetics of LCP-Tacro tablets once-a-day to Prograf® capsules twice-a-day
PI: A. Osama Gaber, M.D.
Dates: Jun 2007-Jan 2009 -
Source: LifeCycle Pharma
Title: A phase 2, open-label, multi-center, randomized trial to demonstrate the pharmacokinetics ofLCP-Tacro tablets once daily and Prograf® capsules twice daily in adult de novo kidney transplant patients
PI: A. Osama Gaber, M.D.
Dates: Oct 2008-Mar 2010 -
Source: LifeCycle Pharma
Title: A phase 2, open-label, multi-center, randomized trial to demonstrate the pharmacokinetics of LCP-Tacro tablets once daily and Prograf® capsules twice daily in adult de novo liver
t ransplant patients
PI: A. Osama Gaber, M.D.
Dates: Nov 2008-Apr 2010 -
Source: Hoffman LaRoche
Type: Clinical Study Grant
Title: A double-blind, randomized, placebo controlled, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza.
PI: A. Osama Gaber, M.D.
Dates: Aug 2007-Jul 2009 -
Source: Viropharma
Type: Clinical Study Grant
Title: A randomized, double-blind study to assess the efficacy and safety of prophylactic use of Marivabar versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants.
PI: A. Osama Gaber, M.D.
Dates: Nov 2007-Apr 2009 -
Source: Wyeth
Type: Clinical Study Grant
Title: A randomized, placebo controlled, double-blind comparative study evaluating the effect of Ramipril on urinary protein excretion in maintenance renal transplant patients converted to Sirolimus.
PI: A. Osama Gaber, M.D.
Dates: May 2008-May 2010 -
Source: Astellas
Type: Clinical Study Grant
Title: A Phase II, proof of concept, randomized, open-label, two arm, parallel group, multi-center study to assess the safety of efficacy FK778 compared with standard care in renal transplant recipients with untreated biopsy-diagnosed BK neuropathy
PI: A. Osama Gaber, M.D.
Dates: 2003-2016 -
Source: Astellas
Type: Clinical Study Grant
Title: A Phase II, randomized, open-label, parallel group, multi-center study to assess the safety of efficacy Prograf/FK778 and Prograf/MMF in de novo kidney transplant recipients
PI: A. Osama Gaber, M.D.
Dates: 2004-2008 -
Source: Immune Tolerance Network and National Institute of Allergic and Infectious Disease
Type: Clinical Study Grant
Title: A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campth-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
PI: A. Osama Gaber, M.D.
Dates: 2004-2010 -
Source: LifeCycle Pharma
Type: Clinical Study Grant
Title: A phase II, open-label, multi-center prospective, conversion study in stable kidney transplant patients to compare the pharmacokinetics of LCP-Tacro tablets once-a-day to Prograf® capsules twice-a-day
PI: A. Osama Gaber, M.D.
Dates: 2007-2008 -
Source: Hoffman LaRoche
Type: Clinical Study Grants
Title: A double-blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients with influenza
PI: A. Osama Gaber, M.D.
Dates: 2007-2008 -
Source: Y’s Therapeutics
Type: Clinical Study Grant
Title: A controlled, randomized, prospective, double-blind, multi-center, phase I/II, intravenous, single-dose, dose-escalation study of the safety, pharmacokinetics, and efficacy of YSPSL for prevention of delayed graft funtionc in patients undergoing cadaveric kidney transplantation, YSPSL.
PI: A. Osama Gaber, M.D.
Dates: 2006-2008 -
Source: Isotechnika, Inc.
Type: Clinical Study Grant
Title: A PhaseII, randomized, multicenter, open-label, concentration controlled, safety study of ISA247 and tacrolimus (Prograf) in denovo renal transplant patients
PI: A. Osama Gaber, M.D.
Dates: 2005-2008 - Source: Roche
Type: Clinical Study Grant
Title: An open label randomized, multicenter study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil; (Cellcept) and Sirolimus (Rapammune)
PI: A. Osama Gaber, M.D.
Dates: 2003-2008
